We can’t show the full text here under this license. Use the link below to read it at the source.
Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial
Effectiveness and safety of weekly semaglutide 2.4 mg for weight loss in people from China
AI simplified
Abstract
At Week 44, 85.4% of participants treated with 2.4 mg achieved a weight loss of at least 5% compared to 26.8% with placebo.
- Mean body weight decreased by 11.8% for those on semaglutide 2.4 mg compared to a 3.5% decrease for those on placebo.
- The estimated treatment difference in weight change was 8.3%, with a high statistical significance (p < 0.0001).
- Adverse events occurred in 92.3% of participants receiving semaglutide 2.4 mg, primarily gastrointestinal disorders.
- In contrast, 82.9% of participants on placebo reported adverse events, with fewer gastrointestinal issues.
AI simplified
Key numbers
-11.8%
Mean Body Weight Reduction
Change from baseline to Week 44 with vs. placebo.
85.4%
Proportion Achieving ≥5% Weight Loss
Compared to 26.8% for placebo at Week 44.
92.3%
Adverse Events Reported
Compared to 82.9% in the placebo group.